Most medications covered on the medical benefit require prior authorization through Specialty Fusion. Click here for a list of the medications authorized by Specialty Fusion*
*Please note: This list is not inclusive of all medications that require prior authorization by Mass General Brigham Health Plan. This list is specific to medical specialty medications that require authorization through Specialty Fusion only.
Online: Access the Specialty Fusion online prior authorization tool through the Provider portal
Phone: 877-519-1908 | Fax: 855-540-3693
Standard Prior Authorization Form | Standard Oncology Prior Authorization Form*
*Please note: Requests for medications used for the treatment of Cancer, including supporting medications, must be submitted on the Standard Oncology Prior Authorization Form.
Check the top of the criteria document for additional information, including program details, benefit designation, and contact information.
Providers who are outside of Mass General Brigham Health Plan provider network, requesting service for a non-PPO member, can submit requests online through the online authorization submission form.
For non-specialty medications covered on the pharmacy benefit and non-formulary medications, please submit prior authorizations to Optum Rx using the information below.
For specialty medications, please submit prior authorizations to Specialty Fusion using the information below.
To find out if a medication requires prior authorization or if it is listed on our formulary* please search the drug look up tool.
*Please note: Medications not listed in the drug look up tool are considered non-formulary and require a medical necessity prior authorization for coverage.
Phone: 877-519-1908 | Fax: 855-540-3693
Standard Prior Authorization Form | Standard Hepatitis C Prior Authorization Form | Standard Synagis Prior Authorization Form | Standard Oncology Prior Authorization Form*
*Please note: Requests for medications used for the treatment of Cancer, including supporting medications, must be submitted on the Standard Oncology Prior Authorization Form.
Check the top of the criteria document for additional information, including program details, benefit designation, and contact information.
Phone: 800-711-4555 | Fax: 844-403-1029
Standard Prior Authorization Form
Check the top of the criteria document for additional information, including program details, benefit designation, and contact information.
For Mass General Brigham Health Plan members, except Mass General Brigham employees, drugs marked as Site of Care on this list must be administered in the home or office setting.
To request other, medically necessary sites of care, please submit a prior authorization through Specialty Fusion. View the policy.
Acthar Gel (repository corticotropin injection)
Adapalene cream, gel, & lotion
Adzynma (ADAMTS13, recombinant-krhn)
Alli (orlistat) - Effective January 1, 2026
Alphanine SD (coagulation factor IX [human])
Alprolix (coagulation factor IX [recombinant], Fc fusion protein)
Alyftrek (vanzacaftor/tezacaftor/deutivacaftor)
Alyglo (immune globulin intravenous, human-stwk)
Amphetamine/dextroamphetamine 3-bead ER capsule (Mydayis)
Attention Deficit Hyperactivity Disorder
Austedo (deutetrabenazine) and Austedo XR (deutetrabenazine ER)
Aveed (testosterone undecanoate injection)
Azmiro (testosterone cypionate injection)
Benefix (coagulation factor IX [recombinant])
Caplyta (lumateperone) capsules
Coagadex (coagulation Factor X [human])
Cobenfy (xanomeline/trospium chloride)
Contrave (naltrexone-bupropion)
Contrave (naltrexone-bupropion) - Effective January 1, 2026
Corifact (coagulation Factor XIII concentrate [human])
Crexont (carbidopa/levodopa extended-release)
Cutaquig (Immune Globulin Subcutaneous (Human) - hipp)
Cuvitru (Immune Globulin Subcutaneous [Human])
Cytogam (Cytomegalovirus Immune Globulin Intravenous [Human])
Dihydroergotamine mesylate nasal spray
Durysta (bimatoprost intraocular implant)
Elfabrio (pegunigalsidase alfa-iwxj)
Enstilar (calcipotriene/betamethasone)
Entresto (sacubitril and valsartan)
Epogen (epoetin alfa recombinant)
Feiba (anti-inhibitor coagulant complex [human])
Follistim AQ (follitropin beta)
Glucagon-like Peptide-1 (GLP-1) Agonist for Diabetes
Glucagon-like Peptide-1 (GLP-1) Agonist for Diabetes - Effective January 1, 2026
Grastek (Timothy grass pollen allergen extract)
Herceptin Hylecta (trastuzumab-hyluronidase-oysk)
Hetlioz (tasimelteon tablets) & Hetlioz LQ (tasimelteon oral suspension)
Hizentra (Immune Globulin Subcutaneous [Human])
HyQvia (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase)
Idelvion (coagulation factor IX [recombinant], albumin fusion protein)
Imkeldi (imatinib) oral solution
Influenza Treatment & Prevention Quantity Limit
Ixinity (coagulation factor IX [recombinant])
Iyuzeh (latanoprost ophthalmic solution)
Jatenzo (testosterone undecanoate)
Kyzatrex (testosterone undeconoate)
Liraglutide (generic Saxenda) - Effective January 1, 2026
Liraglutide (generic Victoza) - Effective January 1, 2026
Lotemax 0.5% ophthalmic ointment
Lotemax SM 0.38% ophthalmic gel
Loteprednol 0.5% ophthalmic gel
Loteprednol 0.5% ophthalmic suspension
Lotrisone (clotrimazole/betamethasone)
Lybalvi (olanzapine/ samidorphan) tablet
Metronidazole 1% gel, foam, & cream
Miebo (perfluorohexyloctane ophthalmic solution)
Mircera (methoxy polyethylene glycol epoetin beta)
Mononine (coagulation factor IX [human])
Mounjaro (tirzepatide) - Effective January 1, 2026
Nayzilam nasal spray (midazolam)
Nexlizet (bempedoic acid/ezetimibe)
Non-Formulary Diabetic Supplies & Test Strip Quantity Limit
Novoseven RT (coagulation factor VIIa [recombinant])
Obizur (antihemophilic factor [recombinant], porcine sequence)
Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq)
Odactra (Dermatophagoides farinae and Dermatophagoides pteronyssinus)
Off-Label Non-FDA Approved Medications
Olpruva (sodium phenylbutyrate)
OmniPod, OmniPod 5, OmniPod Go & OmniPod Dash
Oriahnn (elagolix, estradiol, and norethindrone acetate)
Orkambi (lumacaftor/ivacaftor)
Ozempic (semaglutide) - Effective January 1, 2026
Palforzia (peanut allergen powder)
Pombiliti (cipaglucosidase alfa-atga)
Poteligeo (mogamulizumab-kpkc)
Procrit (epoetin alfa recombinant)
Profilnine (factor IX complex [human])
|
Qsymia (phentermine/topiramate extended-release)
Qsymia (phentermine/topiramate extended-release) - Effective January 1, 2026
QuilliChew ER (methylphenidate hydrochloride)
Quillivant XR suspension (methylphenidate hydrochloride)
Ragwitek (short ragweed pollen)
Rebinyn (coagulation factor IX [recombinant], glycoPEGylated)
Restasis (cyclosporine ophthalmic emulsion)
Retacrit (epoetin alfa recombinant)
Rexulti (brexpiprazole) tablets
Rhopressa (netarsudil ophthalmic solution)
Rinvoq (upadacitinib) and Rinvoq LQ (updacitinib)
Rituxan (rituximab) & Rituxan Hycela (rituximab-hyaluronidase)
Rixubis (coagulation factor IX [recombinant])
Rocklatan (netarsudil and latanoprost ophthalmic solution)
Ruconest (C1 esterase inhibitor [recombinant])
Rybelsus (semaglutide) - Effective January 1, 2026
Rystiggo (rozanolixizumab-noli)
Rytary (carbidopa/levodopa extended-release)
Secuado (asenapine) transdermal patch
SevenFact (factor VIIa [recombinant])
Skytrofa (lonapegsomatropin-tcgd)
Solaraze (diclofenac sodium gel)
Stimufend (pegfilgrastim-fpgk)
Symdeko (tezacaftor/ivacaftor)
Tarpeyo (budesonide controlled-release)
Terbinafine 250mg Quantity Limit
Tlando (testosterone undecanoate)
Tretten (coagulation Factor XIII A-Subunit [recombinant])
Trikafta (elexacaftor/tezacaftor/ivacaftor)
Trulicity (dulaglutide) - Effective January 1, 2026
Vonvendi (von Willebrand factor [recombinant])
Vraylar (cariprazine) capsules
Vusion (miconazole/zinc oxide/white petrolatum)
Vykat XR (diazoxide choline extended-release)
Vyndaqel (tafamidis meglumine)
Vyvgart (efgartigimod alfa-fcab) & Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase)
Wegovy (semaglutide) - Effective January 1, 2026
Weight Loss Medications - Effective January 1, 2026
Wilate (von Willebrand factor/coagulation factor VII complex [human])
Xatmep (methotrexate oral solution)
Xdemvy (lotilaner ophthalmic solution)
Xeljanz (tofacitinib) and Xeljanz XR (tofacitinib extended-release)
Xembify (Immune Globulin Subcutaneous [Human} – klhw)
Xenleta (lefamulin) Oral Tablets
Xiaflex (collagenase clostridium histolyticum)
Xromi (hydroxyurea) oral solution
Xyosted (testosterone enanthate) auto-injector
Xywav (oxybate salts [calcium, magnesium, potassium, and sodium])
Yorvipath (palopegteriparatide)
Zepbound (tirzepatide) - Effective January 1, 2026
Call provider services at 855-444-4647.